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ABSTRACT 
We have developed a chamber model of islet engraftment that optimizes islet survival by rapidly 
restoring islet-extracellular matrix relationships and vascularization. Our aim was to assess the 
ability of syngeneic adult islets seeded into blood vessel-containing chambers to correct 
streptozotocin-induced diabetes in mice. Approximately 350 syngeneic islets suspended in 
Matrigel® extracellular matrix were inserted into chambers based on either the splenic or groin 
(epigastric) vascular beds, or, in the standard approach, injected under the renal capsule. Blood 
glucose was monitored weekly for 7 weeks, and an intraperitoneal glucose tolerance test 
performed at 6 weeks in the presence of the islet grafts. Relative to untreated diabetic animals, 
glycemic control significantly improved in all islet transplant groups, strongly correlating with 
islet counts in the graft (P<0.01), and with best results in the splenic chamber group. Glycemic 
control deteriorated after chambers were surgically removed at week 8. Immunohistochemistry 
revealed islets with abundant insulin content in grafts from all groups, but with significantly 
more islets in splenic chamber grafts than the other treatment groups (P<0.05). It is concluded 
that hyperglycemia in experimental type 1 diabetes can be effectively treated by islets seeded 
into a vascularized chamber functioning as a “pancreatic organoid.” 
Key words: streptozotocin • diabetes • islet transplantation • vascularized chambers • renal 
capsule  
here is a chronic shortage of suitable organ donors for islet transplantation in human type 
1 diabetes (1). It is usually necessary to harvest multiple pancreata to obtain sufficient 
islets for transplantation (2, 3). This has prompted the search for more efficient techniques T 
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 of islet transplantation and engraftment and is the driving force behind the present study using 
vascularized tissue engineering methodology to promote organ function and insulin production. 
The current clinical method of islet transplantation is injection into the portal vein (3, 4). 
Experimentally, islets are injected into the portal vein, into the omental pouch (5), or under the 
renal capsule (6), or microencapsulated prior to their injection into one of these sites (7). Of the 
major factors affecting the long-term viability of transplanted islets, hypoxia is a significant 
problem because islets are particularly susceptible to ischemia-reperfusion injury in the first 48 h 
after transplantation (8,9). In clinical trials, vascular thrombosis (10) and irreversible metabolic 
changes such as liver steatosis (11) have been identified as long-term complications of repeated 
portal vein injection of islets. With microencapsulation, the functional longevity of encapsulated 
islets in vivo may be eventually compromised by cellular overgrowth, despite ongoing attempts 
to maintain long-term membrane porosity (12). 
An isolated but readily accessible chamber with an independent blood supply could improve in 
vivo culture of islets and extend our understanding of the signals required for expansion of 
insulin-producing tissue. Our laboratory has developed several three-dimensional in vivo models 
that can sustain transplanted cells. In the rat, an arteriovenous (AV) loop created by 
anastomosing the divided ends of the femoral artery and vein was sandwiched between layers of 
dermal collagen and the construct contained within a subcutaneously implanted polycarbonate 
chamber in the groin (13). Spontaneous outgrowth from the loop resulted in new fibrovascular 
tissue, which invaded the collagenous scaffold and filled the chamber. A similar model in the 
mouse, in which a flow-through AV pedicle was enclosed in a subcutaneously inserted 
cylindrical silicone chamber, also resulted in angiogenesis and spontaneous generation of 
connective tissue (14). Vascularized tissue growth occurred even in the absence of added 
extracellular matrix (ECM) or cells, substantially filling the chamber within 2–4 weeks (15). By 
4–12 weeks, we found further expansion and maturation of this tissue, with progressively greater 
collagen fibril alignment (16). The addition of various ECM scaffolds within the chamber 
increased the rate of new tissue growth (16). Interestingly, the addition to the mouse chamber of 
specific components, such as Matrigel® and fibroblast growth factor-2 (FGF-2), promoted 
differentiation of adipose tissue (14). In vascularized rat chambers we have also observed the 
growth and differentiation of myoblasts after 2–6 weeks into myotubes and myofibers in the new 
tissue, staining positively for desmin and dystrophin, respectively (17). Theoretically, any 
combination of ECM, cells, and specific growth or differentiation factors may be added to these 
chambers to engineer new tissue. Furthermore tissue can be retrieved easily or further 
components added at any stage. 
Initial experiments with an in vivo vascularized rat chamber seeded with syngeneic islets 
revealed maintenance of immunohistochemical insulin and glucagon expression after 3 weeks 
(18). Similarly, adult mouse islets and fetal mouse pancreata have been shown to survive in 
vascularized chambers in the groin of non-diabetic mice for up to 10 weeks (Cronin, K.J. et al., 
unpublished data). In this study, we used mice with streptozotocin-induced diabetes to evaluate 
islet grafts grown in chambers maintained around the epigastric artery and vein (groin chambers) 
or around the splenic artery and vein adjacent to the pancreas (splenic chambers), compared with 
the “benchmark” renal subcapsular site. Our aim was to demonstrate that the chamber model 
allows the development of an insulin-producing graft containing viable islets, suitable for the 
treatment of diabetes. 
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 MATERIALS AND METHODS 
Animals and ethics considerations 
Experiments performed on adult male C57BL/6j mice (22–28 g) (Animal Resource Centre, 
Perth, Western Australia) were conducted under NHMRC Australia guidelines and as approved 
by the Animal Ethics Committee, St. Vincent’s Hospital Melbourne. Mice were housed in an 
approved facility, on a 12 h day/night cycle, and given food and water ad libitum. 
Streptozotocin-induced diabetes 
Freshly weighed streptozotocin (STZ; Sigma Chemical Co., St. Louis, MO) was dissolved in 
0.01 mol/l tri-sodium citrate buffer, pH 4.5, at 20 mg/ml and administered within 5 min via tail 
vein injection at an initial dose of 0.16 mg/g. Over the next 3 days, mice were checked for excess 
urination and water consumption. At day 5, a saphenous vein bleed was performed under 2% 
flurothane anesthesia and blood glucose (BG) level measured with a glucose oxidase-based 
monitor (MediSense Precision Plus, Abbott Laboratories, Doncaster, Victoria, Australia). Only 
mice with non-fasting BG>17 mmol/l and polyuria were defined as diabetic and included in the 
study. Mice that did not initially develop diabetes (~50% of all mice) were re-injected with half 
the initial dose of STZ (0.08 mg/g) and BG measured again at day 5. Using this protocol, ~70% 
of STZ-injected mice became diabetic. 
Islet isolation 
Islets were isolated from C57BL/6 mice as described previously (19). The common bile duct was 
cannulated, and the pancreas was distended with 3 ml RPMI medium (Life Technologies, 
Gaithersburg, MD) containing 1.3 U/ml of collagenase P (Roche Molecular Biochemicals, IN). 
Pooled pancreata were digested at 37°C for 20 min then disrupted with shaking. Islets purified 
on a Histopaque-1077 density gradient (Sigma) were washed and cultured at 37°C in 5% CO2 in 
CMRL medium-1066 (Life Technologies) containing 10% FCS antibiotics, and glutamine for no 
more than two days prior to transplantation. The yield was usually 150–250 islets per mouse, and 
islets of variable size were noted. The islets maintained their morphological integrity and 
viability during culture in complete CMRL medium prior to transplantation. 
Immediately prior to surgery, 400 hand-picked islets were collected into a sterile Erlenmeyer 
tube, washed three times with PBS, and centrifuged to remove FCS. The islets were finally re-
suspended in 50 μl Matrigel® (BD Biosciences, Bedford, MA) at 4°C for seeding into one 
chamber or injecting into the right kidney. On average, ~45 μl of the islet suspension, 
corresponding to ~350 islets, was injected into the chambers or the kidney. 
Surgery 
Vascularized splenic chamber 
Mice were anaesthetized with chloral hydrate (4 mg/g body weight, i.p.), and surgery was 
performed under aseptic conditions. Cylindrical silicone chambers made from laboratory tubing 
(Dow-Corning Corporation, Midland, MI) were cut into segments (5.5 mm in length, 3.35 mm 
internal diameter, volume approx 50 μl) each having a lateral slit. The abdominal hair was 
removed using depilatory cream, and the skin was decontaminated with alcohol and 
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 chlorhexidine. A midline abdominal incision exposed the abdominal contents. The branch of 
splenic artery, where it exited the pancreas, was identified, and adherent adipose tissue was 
dissected from the vessels to create a 1 cm length of splenic pedicle. The chamber was inserted 
around this pedicle. The distal end and the lateral split were sealed with Ethicon Bone WaxTM 
(Johnson and Johnson International, European Logistics Centre, Brussels, Belgium). The islets in 
Matrigel® (50 μl) in a cooled syringe were injected into the open (proximal) end of the chamber 
then sealed with bone wax, taking care not to damage the pedicle (Fig. 1A). The splenic 
chambers were kept in position by the pressure exerted from surrounding organs and suture 
stabilization was not therefore required. The abdomen was closed in layers, with 6/0 nylon 
sutures for the abdominal wall and stainless steel clips for the skin. 
Vascularized groin chamber 
This model has been described previously in detail (14). In outline, using mice anesthetized with 
chloral hydrate as described above, hair on the groin and upper legs of mice was removed using a 
depilatory cream, and the skin was decontaminated using alcohol and chlorhexidine. An incision 
was made above the groin fat pad, from the groin crease to the knee. Superficial epigastric 
vessels were dissected free of surrounding fat from their origin at the femoral vessels for a 
distance of ~1 cm to their point of entry into the groin fat pad. The entire fat pad was mobilized 
free of skin so that the epigastric vessels (free of fat) could be embodied into the cylindrical 
chamber via a lateral split. The whole chamber was anchored to underlying muscle using 10/0 
nylon microsutures. A small amount of the fat pad was used to plug the distal end of the 
chamber. The lateral slit was sealed with bone wax and the chamber filled with ~50 μl of islets 
suspended in Matrigel® from a pre-cooled syringe with a 25-gauge needle. The proximal end of 
chamber was sealed with bone wax (Fig. 1B), and the skin was closed with stainless steel clips. 
Renal subcapsular injection 
Using mice anesthetized as described above, we made a midline abdominal incision, the right 
kidney was identified and islets suspended in 50 μl of Matrigel® were injected slowly through a 
26-gauge needle, with the needle tip close to the surface of the capsule. During injection, care 
was taken so that the needle passed only through the renal capsule without penetrating the body. 
The needle was removed without apparent fluid loss. The abdomen was closed as per the splenic 
chamber operation. 
Sham operation 
All procedures were performed as above, except that Matrigel® minus islets was used to fill the 
chamber. 
Daily care of diabetic mice, weekly blood glucose monitoring 
Mice in the study groups had daily Clinistix™ urine glucose tests (Bayer). One unit of long-
acting insulin (Monotard; diluted 1 in 10, 0.1 ml) was injected subcutaneously if urine glucose 
was positive. The injection sites were rotated between the back of neck and two lumbar regions. 
After operation, non-fasting BG levels were determined weekly on saphenous vein samples. In 
weeks 6, 8, and 10, glucose tolerance tests, chamber harvesting and fasting BG, respectively, 
were performed. 
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 Glucose tolerance test and fasting blood glucose determination 
An intraperitoneal (i.p.) glucose tolerance test (GTT) was performed 6 weeks after surgery. Mice 
were fasted for 6–8 h, with only water provided ad libitum. BG was measured by right saphenous 
vein sample immediately prior to i.p. injection of 0.2 ml of a 250 mg/ml solution of D-glucose 
dissolved in saline (2 mg/g body weight). BG was again measured 30, 60, 90, 120, and 180 min 
after glucose injection. The left saphenous vein was sampled if there was any difficulty obtaining 
a drop of blood from the right vein. “Glucose tolerance” was defined as the insulin-dependent 
glucose uptake in 1 h (20). In the context of the GTT, the BG level at 90/120 min minus BG 
level at time 0 should be ≤50% of the maximal BG level at 30/60 min minus BG level at time 0, 
to be regarded as an “effective” treatment (20). 
Ten weeks after surgery, once splenic and groin chambers had been harvested, fasting BG levels 
were determined for these two groups only. 
Chamber harvest and graft evaluation 
Mice were anesthetized as described earlier, and the chambers or kidneys were removed via a 
minimal access incision, 8 weeks after the initial operation. At the time of harvest, the size of 
tissues and patency of the pedicle were assessed qualitatively. Mice from the splenic and groin 
chamber groups were allowed to recover for the two weeks prior to the fasting BG 
determination, before being killed by an i.p. injection of Lethobarb (0.3 ml, pentobarbitone 
sodium; Virbac, Sydney, NSW, Australia) at week 10. In the renal subcapsular group, both 
kidneys were removed for histology and the mice were killed at week 8. 
Histology and immunohistochemistry 
Tissue was fixed overnight in 4% formaldehyde, before being processed and embedded into 
paraffin. Serial sections (5 μm) were placed on slides coated with 3-aminopropyltriethoxysilane 
(Sigma), dried overnight in a 37°C incubator, and stained with hematoxylin and eosin (H&E). 
Immunohistochemical staining to identify α (glucagon), β (insulin), and delta (somatostatin) 
cells in islets was performed on a commercial autostainer (DAKO, Carpinteria, CA). Slides were 
washed with PBS, incubated for 5 min with 3% hydrogen peroxide, then for 30 min with primary 
antibodies: guinea pig anti-insulin antibody diluted 1:10, rabbit anti-glucagon antibody diluted 
1:200 or rabbit anti-somatostatin antibody diluted 1:100 (DAKO). The components of the rabbit 
EnVision plus detection system (DAKO) were then applied for 30 min, followed by 
diaminobenzaldehyde reagent for 5 min. The slides were counterstained with hematoxylin. 
Rabbit non-immune serum was substituted for negative controls, and normal pancreas sections 
were tested as positive controls. 
Morphological assessment 
Sections were selected every 100 μm throughout each tissue graft, assuming an average islet 
diameter of 100–130 μm. Specimens harvested from splenic or groin chambers were stained with 
H&E, whereas those from the kidney were immunostained with insulin antibody. With the 
observer blinded to the origin of the specimen, each slide was observed at ×2 and then ×20 
magnification. Islets were quantified and their relative positions in the specimen were recorded, 
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 taking care not to duplicate counting of the same islet in consecutive sections. The total islet 
count for each specimen was compiled. 
To assess the degree of vascularization of the surviving islets in the grafts, the distance between 
each islet and the nearest blood vessel (of >20 μm diameter) was determined using the 
AxioVision, version 4.2, image processing and analysis system based on the Zeiss Axioscope 2 
microscope (Carl Zeiss Vision, Munich, Germany). 
Statistics 
Data are reported as mean ± standard deviation (SD) for all observations, where n equals the 
number of mice. Statistical comparisons between groups, using ANOVA and a post-hoc Tukey’s 
multiple comparison test, were considered significant at P ≤ 0.05 (GraphPad Prism software, San 
Diego, CA). The relationship between the “glycemic control index” and total islet counts per 
specimen was determined by least-squares regression analysis using SPSS for Windows version 
12.01. 
RESULTS 
Evaluation of grafts in chambers 
At the time of harvest, the vascular pedicle was patent in all chambers. After 6 weeks’ growth, 
tissue occupied ~50% of the chamber volume for splenic chambers and ~90% of the chamber 
volume for groin chambers, most of the latter appearing to be vascularized fat. 
Weekly BG levels 
The mean weekly BG levels for the control and groups over 10 weeks are shown in Table 1. The 
mean BG for non-diabetic mice was in the range 7–10 mmol/l and for STZ-induced diabetic 
mice 18–22 mmol/l. BG levels for sham-operated mice were indistinguishable from non-
operated counterparts. BG in splenic chamber, groin chamber, and renal subcapsule groups 
exhibited a gradual fall in the first 4 weeks, stabilizing between weeks 4 to 7, and reaching 
minimal levels of 10.9, 14.1, and 12.1 mmol/l, respectively, by week 7. Compared with untreated 
diabetic controls, these decreases in BG of 8.1, 8.2, and 7.2 mmol/l were significant in all three 
groups (P<0.001). However, only the splenic chamber group reached the threshold BG level of 
11.1 mmol/l, regarded as a significant reversal of hyperglycemia (21). The decrease in BG 
achieved by the splenic chamber group was significantly better than that of the groin chamber 
group (P<0.01). However, no significant differences were found in BG between the splenic 
chamber and renal subcapsule groups, nor between the groin chamber and renal subcapsule 
groups. Once the islet-containing chambers had been harvested, the mean BG returned to near 
pre-operative levels in both splenic and groin chamber groups (P<0.05 in BG at week 9 vs. BG 
at week 7). 
Glucose tolerance test 
An i.p. GTT was performed 6 weeks after islet grafting (Fig. 2). Fasting BG in normal or sham-
operated mice was around 7.0 mmol/l. Following i.p. glucose BG typically peaked at 12 mmol/l 
after 30–60 min and returned to near-normal fasting levels of 7.7 mmol/l by 120 min (mean 
hourly glucose uptake being 87% of the i.p.-injected glucose bolus). By contrast, diabetic control 
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 mice had a fasting BG of 13.8 mmol/l, which peaked at 22.2 mmol/l at 30–60 min after i.p. 
glucose, and was still significantly elevated at 20.3 mmol/l after 120 min (mean hourly glucose 
uptake being 22% of the i.p.-injected glucose). The splenic chamber, groin chamber, and renal 
subcapsule groups had mean hourly uptakes of 40, 27, and 28% of the i.p.-injected glucose, 
respectively, which is less than the 50% hourly glucose uptake regarded by Abel et al. (20) as 
“effective” treatment of hyperglycemia. All three groups had diminished capacity for glucose 
tolerance compared with normal/no-operation control mice (P<0.01). 
Morphological evidence of islet survival, hormone production, and vascularization 
After 8 weeks’ growth H&E staining revealed isolated surviving islets in the chamber tissue. 
Each cross section studied had between 0 and 7 islets, an average of 1 islet in every 2 sections 
examined. Patent pedicles and well-dispersed small blood vessels were observed in tissue from 
both splenic and groin chambers. Fibrous responses were seen at the edge of tissues. They were 
generally free of inflammatory infiltrates (Figs. 3A and 4A). At higher magnification, we 
observed that islets had maintained their rounded morphology in the chamber tissue. 
Vascularized adipocytes were seen in the middle of the chamber tissue (Figs. 3C and 4B–E), and 
more numerous small blood vessels were seen in the fibrous zone (Figs. 3C and 4A, D). Islets 
were commonly located in vascularized connective tissue or adipose tissue at the periphery of the 
graft (Fig. 4B–D) and were readily identified by their immunochemical staining for insulin, 
glucagon, and somatostatin (Figs. 3B–D and 4C–E). Islets injected under the renal capsule were 
more difficult to identify due to the similar histological appearance of the glomeruli (Fig. 5A). 
One islet, identified by insulin immunostaining, had a flattened morphology (Fig. 5B), but others 
had a more rounded in appearance (Fig. 5C). 
Islets surviving after 8 weeks’ growth were commonly located adjacent to a large artery or vein. 
Morphological analysis of islets in graft tissue harvested from splenic chambers and groin 
chambers revealed that, on average, islets were 41.7 ± 27.7 μm (n=29) and 47.7 ± 34.8 μm 
(n=40), respectively, from a major blood vessel. Interestingly some islet clusters had capillaries 
passing directly through them (Fig. 4B). Compared with the rich vasculature in the chamber 
tissue, blood vessels were difficult to identify in the kidney specimens, so this parameter was not 
determined for islets in the renal subcapsule group. 
Quantification of islet survival in grafts after 8 weeks and correlation with BG 
The mean numbers of islets in grafts were 70 ± 22 (range 4–120) in the splenic chamber group, 
23 ± 5 (range 7–42) in the groin chamber group, and 19 ± 11 (range 0–66) in the renal 
subcapsule group. The splenic chamber group had significantly more surviving islets than the 
other two groups (P<0.05). Given that on average 350 islets were seeded, the mean islet survival 
was 22, 7, and 6%, respectively (range 0 to 37%). 
Glycemic control during islet transplantation in vascularized chambers was estimated by plotting 
the minimal BG in weeks 1–8 against total islet counts in the graft specimen harvested at week 8. 
Regression analysis showed a strong correlation between these two parameters (r=–0.68, 
P<0.01) (Fig. 6). 
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 DISCUSSION 
In this study, we have shown that islets seeded into vascularized chambers reduce hyperglycemia 
in STZ-induced diabetic mice just as effectively as islets injected under the renal capsule, the 
“benchmark” procedure (6). 
Properties of vascularized chambers that promote islet survival 
Several factors influence the viability of transplanted islets. Hypoxia is likely to be one of the 
major causes of islet loss soon after transplantation. Folkman and co-workers determined that, 
ideally, cells need to be within 150–200 μm of a blood vessel in order to receive adequate 
oxygen and nutrition for survival (22). Our morphological study on tissue at 8 weeks 
demonstrated that surviving islets were, on average, 45 μm from a major blood vessel (range 6–
118 μm), well within the survival limits defined by Folkman. Islets injected under the renal 
capsule also become hypoxic, because normoxia is limited to a few cell layers before critical 
ischemia occurs (23, 24). During islet isolation, islet-basement membrane interactions are 
disrupted by collagenase digestion. In vitro studies have shown that laminin-1 promotes survival 
and differentiation of β cells (25). The use of laminin-rich Matrigel® as a carrier for islets in the 
vascularized chambers is designed to restore islet-laminin interactions and improve islet survival. 
Once seeded into the chamber, islets should benefit from both the angiogenic and adipogenic 
properties of Matrigel® (26). However, the time spent at 4°C (necessary for keeping Matrigel® 
in its liquid form prior to islet seeding) may be critical, as this temperature is considered too low 
for optimal β cell survival (27). 
The lag-time before the decline of BG after islets are seeded into vascularized chambers or 
injected under the renal capsule may reflect the time taken for islet engraftment within a new 
vascular bed. Patency of the vascular pedicle was maintained in all chambers and, histologically, 
marked angiogenesis was observed throughout the entire tissue. Quantitative morphological 
studies after 8 weeks showed that glycemic control was improved with as few as 50 (~14%) of 
the 350 islets surviving in chambers or under the renal capsule. Importantly, a strong correlation 
was also found between the minimal BG achieved by islet transplantation in chambers and the 
number of islets found in the specimen by morphological analysis (P<0.01). Endocrine function 
was confirmed by the increase in glycemia after the chambers were surgically removed at 8 
weeks, and by immunohistochemical staining for insulin, glucagon and somatostatin. 
Optimal site of chamber for islet transplantation 
The lower mean BG over time, lower fasting glucose levels, improved glucose uptake during the 
GTT, and the higher islet counts per graft demonstrate that the splenic chamber group had better 
glycemic control than the groin chamber group. Splenic chambers inserted in the pancreatic bed 
use the same portal drainage as native islets, whereas chambers inserted in the groin have 
systemic drainage. Portal drainage has been shown to provide more effective and physiological 
function of islets (28). Groin chambers, however, may have an advantage of maintaining long-
term patency of the pedicle because superficial epigastric vessels, branching from femoral 
vessels, form anastomoses with ilio-inguinal vessels. This may result in arterial input and venous 
drainage from both sides (13). We would expect the angiogenic capacity of the two locations to 
be similar. Relatively more tissue formed in groin chambers compared with splenic chambers, 
and qualitatively a greater percentage of adipose tissue was found in the groin chambers. Islets 
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 were located in both the connective tissue and the adipose tissue, with no apparent preference. In 
all cases the islets were close to blood vessels, indicating that vascularization is crucial for their 
survival and function. Of particular interest was the finding of multiple capillaries in some 
revascularized islets, a typical example is shown in Fig. 4B. This intimate association between 
islet and the bloodstream is vital for the islet’s ability to sense hyperglycemia, to respond by 
producing insulin then to secrete the hormone efficiently into the bloodstream. 
The renal subcapsule group had BG levels intermediate between the splenic and groin chamber 
groups but were not statistically different from either. These BG levels were significantly better 
than untreated diabetic controls (P<0.001). The renal subcapsular site has been shown previously 
to maintain effective islet function compared with intrahepatic and other sites in rats and mice 
(23, 24) due, in part, to the ready access of a blood supply (28, 29) and rapid revascularization 
rate (24). Most parameters suggest that vascularized chambers are at least comparable with this 
“benchmark” islet transplantation procedure. Furthermore, data from the islet counts per 
specimen demonstrated the survival of significantly more islets on average in vascularized 
splenic chambers compared with either the renal subcapsule or the vascularized groin chamber 
groups (P<0.05). 
Potential clinical application of this technique 
The clinical method of choice for islet transplantation is portal vein injection, although 
thrombosis after repeated injections and long-term metabolic disturbances in the liver such as 
steatosis are significant complications of this procedure (10, 11). Whole pancreas transplantation 
is another alternative but, as with islet transplantation, suffers from a chronic lack of pancreata 
(2, 3). 
The chamber model is a useful experimental tool, but would need to undergo revision before it 
could become the clinical method of choice. The surgery involved requires considerable 
expertise and may be too complex to be performed routinely by a general surgeon. Surgical 
insertion of chambers is an invasive procedure and the introduction of infection is a further 
complication. In its present form, the chamber technique cannot effectively protect islets from 
allorejection or recurrence of autoimmunity, but it could be combined with cell protection 
techniques such as islet microencapsulation (12, 30) to overcome this problem and improve the 
outcome. The islets most distant from the pedicle are subject to hypoxia in the early days after 
engraftment (8, 9, 31). It may be advantageous in the future to attempt seeding islets directly 
onto the pedicle in a smaller volume of carrier solution (e.g., 10–20 μl) to minimize islet loss. 
The strategy of delaying the introduction of islets into chambers by 1 to 2 weeks, the time taken 
to establish an adequate angiogenic response in the mouse model (14), could ultimately improve 
islet engraftment and viability. Nevertheless, vascularized chambers have some distinct 
advantages. Chambers can be located on blood vessels of choice, such as the splenic vessels, 
offering portal vein drainage of the islet-containing graft. Furthermore, the contents of the 
chamber could theoretically be replenished with fresh islets if the original islets lose their ability 
over time to produce insulin. Only time and further refinement of the technique will prove 
whether it has a future as a viable clinical method of islet transplantation. 
The use of the tissue-engineered, insulin-producing “organoid,” with its intrinsic vascular supply, 
the use of autologous cells and biomaterials (where possible), and the ability to retrieve or even 
replenish seeded islets, could overcome several deficiencies in the currently available methods of 
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 islet transplantation. In this novel model the graft environment can be altered via ECM 
substitution, cellular co-culture, and concurrent growth factor or drug administration. 
Furthermore, the transplanted tissues are recoverable without animal sacrifice and are 
microsurgically transferable within and between individuals. Due to its independent vascular 
supply, manipulation, analysis, and evaluation are simplified; for example, blood sampling from 
the afferent and efferent pedicle to assess insulin production by the transplanted islets is 
theoretically feasible. The model provides an in vivo culture system for the study of islet 
transplantation and lends itself to the introduction of pancreatic stem cells and islet precursor 
cells. 
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TABLE 1. Weekly nonfasting blood glucose (mmol/l; meanSD) for splenic chamber, groin chamber, and renal subcapsule groups, normal



























0 19.0  1.9 22.3  4.8 19.3  3.4 — — 19.2  2.3 18.1  0.6
1 16.0  2.4 17.5  3.9 15.0  4.1 10.1  0.6 7.8  1.1 18.6  2.8 17.9  2.1
2 12.5  2.0 19.0  4.3 15.1  4.6 9.7  0.9 9.8  1.4 18.1  3.6 20.6  7.9
3 11.6  1.8 16.5  3.8 14.0  4.5 8.5  0.8 9.4  1.4 18.1  2.0 19.0  5.0
4 11.4  1.4 15.4  3.8 12.1  2.7 9.7  1.0 8.8  1.2 20.2  5.0 18.4  3.6
5 11.8  2.2 14.4  3.5 12.8  3.4 8.8  0.4 6.8  0.8 18.5  1.2 18.8  0.3
6 GTT
7 10.9  1.0 14.1  3.1 12.6  3.7 NMb NM 20.6  2.0 20.0  3.3
8 Chamber harvest
9 14.4  2.4 20.1  5.7 NM NM NM NM NM
10 Fasting BG






Figure 1. Vascularized chamber models. A) Splenic chamber with blood vessels, Matrigel® and islets, immediately prior 
to sealing the end of the chamber with bone wax. B) Groin chamber, showing the sealed silicone tube (S) encasing the 
inferior epigastric arteriovenous pedicle, Matrigel® and islet tissue. The proximal epigastric vessels (PV) are seen to the 
right of the silicone tube and the distal vessels (DV) still encased in adipose tissue on the left. 
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Figure 2. Mean blood glucose levels in the intraperitoneal glucose tolerance test (GTT) performed 6 weeks after 
transplantation of islets. 
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Figure 3. Histological sections of islets in a splenic chamber 8 weeks after transplantation. A) Islets (I) grouped together 
in a splenic chamber (H&E, ×100). B) An adjacent section of the same islets as in (A) stained with insulin antibody 
(×100). C) Islets in splenic chamber stained with glucagon antibody (×100).  D) Islets in splenic chamber stained with 
somatostatin antobody (×100). 
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Figure 4. Histological sections of islets in a groin chamber 8 weeks after transplantation. A) An islet (I) in vascularized 
Matrigel® adjacent to the patent pedicle (P) (H&E, ×50). B) Two adjacent islets (I) close to blood vessels (P) in the tissue 
and containing numerous capillaries within each islet (H&E, ×100). C; left) An islet stained with insulin antibody (×100).  
D; middle) An islet stained with glucagon antibody (×100).  E; right) An islet stained with somatostatin antibody (×100). 
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Figure 5. Histological sections of islets injected under the renal capsule after 8 weeks. A) An islet under the renal capsule 
(H&E, ×200). Note the difficulty in distinguishing this islet from the surrounding tissue of the kidney. B) The same islet 
depicted in (A) stained with insulin antibody (×200), allowing its ready identification compared with surrounding tissue. C) 
A group of islets stained with insulin antibody (×100) close to the surface of the renal capsule. 
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Fig. 6 
 
                
 
Figure 6. Relationship between minimal blood glucose during islet transplantation and total islet count per graft. The data 
is from all three treatment groups. 
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